Merck & Co., Inc. (NYSE:MRK) Cut to Sector Perform at Royal Bank Of Canada

Royal Bank Of Canada lowered shares of Merck & Co., Inc. (NYSE:MRK) from an outperform rating to a sector perform rating in a report published on Thursday, Marketbeat.com reports. They currently have $150.00 target price on the stock, up from their prior target price of $142.00.

MRK has been the topic of a number of other research reports. Wall Street Zen cut Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. Argus raised their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Scotiabank boosted their price objective on Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a report on Tuesday, June 30th. Citigroup started coverage on Merck & Co., Inc. in a research report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price objective on the stock. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $120.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Fifteen analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and a consensus target price of $144.10.

Merck & Co., Inc. Stock Performance

Shares of NYSE:MRK opened at $152.43 on Thursday. The company has a market capitalization of $376.07 billion, a price-to-earnings ratio of 121.94, a PEG ratio of 6.58 and a beta of 0.19. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $154.49. The firm’s 50-day moving average is $128.09 and its 200 day moving average is $121.23. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the prior year, the company posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Research analysts predict that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.2%. Merck & Co., Inc.’s payout ratio is presently 272.00%.

Insider Buying and Selling

In other news, EVP David R. Maraldo sold 18,706 shares of the stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the transaction, the executive vice president owned 18,212 shares of the company’s stock, valued at approximately $2,344,248.64. This represents a 50.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jennifer Zachary sold 80,315 shares of the firm’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total value of $10,718,839.90. Following the transaction, the executive vice president owned 45,509 shares in the company, valued at approximately $6,073,631.14. This represents a 63.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 228,238 shares of company stock valued at $29,977,783 over the last 90 days. 0.17% of the stock is owned by insiders.

Institutional Trading of Merck & Co., Inc.

Hedge funds have recently added to or reduced their stakes in the business. D.A. Davidson & CO. grew its holdings in Merck & Co., Inc. by 4.4% in the fourth quarter. D.A. Davidson & CO. now owns 576,959 shares of the company’s stock worth $60,731,000 after purchasing an additional 24,576 shares during the last quarter. Pinnbrook Capital Management LP lifted its holdings in shares of Merck & Co., Inc. by 95.2% during the 4th quarter. Pinnbrook Capital Management LP now owns 23,280 shares of the company’s stock valued at $2,450,000 after purchasing an additional 11,355 shares during the last quarter. Cibc World Market Inc. boosted its position in shares of Merck & Co., Inc. by 32.6% in the 4th quarter. Cibc World Market Inc. now owns 1,301,744 shares of the company’s stock worth $137,022,000 after purchasing an additional 320,143 shares in the last quarter. Handelsbanken Fonder AB grew its stake in Merck & Co., Inc. by 13.9% during the 4th quarter. Handelsbanken Fonder AB now owns 1,843,042 shares of the company’s stock worth $193,999,000 after buying an additional 224,752 shares during the last quarter. Finally, Panagora Asset Management Inc. grew its stake in Merck & Co., Inc. by 410.5% during the 4th quarter. Panagora Asset Management Inc. now owns 705,442 shares of the company’s stock worth $74,255,000 after buying an additional 567,249 shares during the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their personalized cancer therapy met key Phase 3 goals, improving recurrence-free and distant metastasis-free survival for high-risk melanoma patients when added to Keytruda. The result is the first major late-stage win for an mRNA cancer vaccine and strengthens the potential for regulatory approval and broader oncology applications. MRK/MRNA’s Personalized Cancer Therapy Delivers First Phase III Win
• Positive Sentiment: Several Wall Street firms raised their outlooks for MRK: Goldman Sachs increased its price target to $160 and kept a Buy rating, while BMO raised its target to $170 and UBS lifted its target to $175. Morgan Stanley also upgraded the shares to Overweight with a $179 target after the cancer-trial success.
• Positive Sentiment: Investors see Merck’s newer products, acquired assets and pipeline programs as a potential growth cushion against Keytruda’s eventual patent expiration. The company’s expanding portfolio could help diversify revenue beyond its flagship drug. Can Merck’s New Drugs Offer Growth Cushion Ahead of Keytruda LOE?
• Neutral Sentiment: Unusually high options activity indicates heightened investor interest and potential volatility, but it does not by itself establish the direction of the stock.
• Negative Sentiment: RBC Capital Markets downgraded Merck to Sector Perform and set a $150 target, arguing that execution risks and the 2028 Keytruda loss of exclusivity are being underestimated. RBC said near-term catalysts are attractive, but the stock’s valuation leaves limited room for additional gains. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Negative Sentiment: Jefferies separately moved Merck from Strong Buy to Hold. The central concern is that the shares have already rallied substantially on the trial news, making the current valuation appear demanding relative to the remaining patent and execution risks.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.